C4 Therapeutics (CCCC) vs Ocugen (OCGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
C4 Therapeutics (CCCC) has outperformed Ocugen (OCGN) over the past year, gaining 24.8% versus a loss of 43.2%. Over five years, OCGN leads with a -88.5% price change compared with -93.6% for CCCC. C4 Therapeutics is the larger company by market cap ($346.9 million vs $339.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | OCGN |
|---|---|---|
| Share price | $2.82 | $1.00 |
| Market cap | $346.93M | $339.11M |
| 1-day change | -2.08% | -3.85% |
| YTD return | +47.64% | -25.93% |
| 1-year return | +24.78% | -43.18% |
| 5-year return | -93.57% | -88.45% |
| EPS (TTM) | $-0.91 | $-0.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.17 | $2.73 |
| 52-week low | $1.69 | $0.97 |
| Distance from 52-week high | -45.45% | -63.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +372.70% | +1117.00% |
| Average volume | 2.39M | 5.82M |
| Shares outstanding | 123.03M | 339.11M |
| Employees | 104 | 116 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CCCC has outperformed OCGN by 68.0 percentage points over the past year.
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
About Ocugen
OCGN stock →Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.
Healthcare · Biotechnology · 116 employees
CCCC vs OCGN FAQ
Which is bigger, C4 Therapeutics or Ocugen?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $346.93M compared with $339.11M for Ocugen (OCGN).
Which stock has performed better over the past year, CCCC or OCGN?
CCCC returned +24.78% over the past 12 months, compared with -43.18% for OCGN (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Ocugen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.